These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38965541)

  • 21. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.
    Yu AP; Guérin A; Ponce de Leon D; Ramakrishnan K; Wu EQ; Mocarski M; Blum S; Setyawan J
    J Med Econ; 2011; 14(4):486-96. PubMed ID: 21679019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.
    Resta E; Scioscia G; Lacedonia D; Quarato CMI; Panza F; Resta O; Lepore G; Buonamico E; Di Lecce V; Carpagnano GE; Barbaro MPF; Rossi N
    BMC Health Serv Res; 2022 Oct; 22(1):1283. PubMed ID: 36284319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Nannini LJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can electronic monitoring with a digital smart spacer support personalised medication adherence and inhaler technique education in patients with asthma?: Protocol of the randomised controlled OUTERSPACE trial.
    Dierick BHJ; Achterbosch M; Been-Buck S; Klemmeier T; van de Hei SJ; Hagedoorn P; Kerstjens HAM; Kocks JWH; van Boven JFM
    BMJ Open; 2022 Jun; 12(6):e059929. PubMed ID: 35697450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial.
    Davis E; Marra C; Gamble JM; Farrell J; Lockyer J; FitzGerald JM; Abu-Ashour W; Gillis C; Hawboldt J
    Trials; 2016 Oct; 17(1):502. PubMed ID: 27737686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
    Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS
    Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD.
    Miravitlles M; Marín A; Huerta A; Carcedo D; Villacampa A; Puig-Junoy J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1643-1654. PubMed ID: 32764910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
    Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaler Technique and Adherence to Inhaled Medications among Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam.
    Ngo CQ; Phan DM; Vu GV; Dao PN; Phan PT; Chu HT; Nguyen LH; Vu GT; Ha GH; Tran TH; Tran BX; Latkin CA; Ho CSH; Ho RCM
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30634631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial.
    Gregoriano C; Dieterle T; Breitenstein AL; Dürr S; Baum A; Maier S; Arnet I; Hersberger KE; Leuppi JD
    Respir Res; 2018 Dec; 19(1):237. PubMed ID: 30509268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Long H; Xu H; Janssens JP; Guo Y
    Respir Res; 2021 Jul; 22(1):209. PubMed ID: 34301267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD.
    Bourbeau J; Bafadhel M; Barnes NC; Compton C; Di Boscio V; Lipson DA; Jones PW; Martin N; Weiss G; Halpin DMG
    Int J Chron Obstruct Pulmon Dis; 2021; 16():499-517. PubMed ID: 33688176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
    Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD.
    Kahle-Wrobleski K; Bui BKH; Friderici J; Moore KJ; Carlyle M; Webb NS; Martin CK; Pace WD; Westfall JM
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1357-1373. PubMed ID: 38912054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.